Myxomatous mitral valve disease / MMVD (NEBL risk panel) - Dog

What does this test examine?

This genetic test analyses three NEBL risk markers used for myxomatous mitral valve disease, also known as MMVD, degenerative mitral valve disease or chronic mitral valve disease in dogs.

The analysis includes NEBL1 chr2:11816535A>G, NEBL2 chr2:11823576C>T and NEBL3 chr2:11979724G>A. Together these markers provide extra information about the genetic risk profile for MMVD in relevant breeds.

What does this condition mean?

MMVD affects the mitral valve, making it close less effectively. This can lead to valve leakage, heart murmur, heart enlargement and a higher chance of cardiac problems over time. In small dog breeds it is an important topic for breeding selection and follow-up.

MMVD is a complex trait. The NEBL markers should therefore be interpreted as risk markers: they provide valuable genetic information, while the final course is also influenced by other genes, age and individual background.

Inheritance and result

For this application the trait is treated as multifactorial and polygenic. The result shows for each marker whether the dog carries the favourable reference genotype, a mixed genotype or two risk alleles.

Practical value of this test

• Breeders receive three separate marker results that together help assess the genetic MMVD risk profile.
• The test supports selection of breeding animals and mating combinations, especially when MMVD is important within lines or related breeds.
• The result helps include genetic variation around the NEBL region more consciously in breeding plans.
• Reporting the three markers separately keeps clear which marker is favourable, mixed or increased-risk.